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Purpose or Objective: NRG/RTOG 0813 is a phase I/II study 
designed to determine the maximal tolerated dose (MTD) and 
efficacy of SBRT for NSCLC with centrally located tumors. We 
hereby report the primary endpoint of the phase I portion of 
the study. 
 
Material and Methods: Medically inoperable pts with biopsy 
proven, PET staged T1-2 (<5cm)N0M0 NSCLC and centrally 
located tumors (within or touching the zone of the proximal 
bronchial tree or adjacent to mediastinal or pericardial 
pleura) were successively accrued onto a dose-escalating 5 
fraction SBRT schedule ranging from 10-12 Gy/fraction 
delivered over 1.5-2 weeks. Dose-limiting toxicity (DLT) was 
defined as any grade 3 or worse toxicity (per CTCAE v.4) 
occurring within first year, possibly, probably, or definitely 
related to treatment from a pre-specified list of cardiac, 
esophageal, respiratory or neurological toxicities. Any 
potential DLT within the initial year post-SBRT could have led 
to dose reduction for subsequent patients accrued, using 
TITE-CRM (time-to-event continual reassessment method) 
statistical design. MTD was defined as SBRT dose associated 
with a 20% probability of DLT.  
 
Results: 120 pts were accrued Feb 2009 to Sept 2013 from 43 
participating centers. Numbers (n) accrued into each cohort, 
n eligible for analysis (20 pts were excluded as they did not 
receive protocol treatment (12) or were ineligible (8)), and n 
evaluable for DLT analyses (11 not evaluable, 10 of whom 
died in the first year without a DLT) are shown in the table. 
Pts were elderly (median age 72), slightly more females 
(57%), majority had performance status 0-1 (84%). Most 
cancers were T1 (65%) and squamous cell (45%). Median 
follow up was 26.6 months. There were 5 events that met the 
definition of DLTs; Table details the protocol pre-specified 
DLTs and the worst treatment-related AEs (ie occurring at 
any time). MTD is 12.0 Gy/fr; Bayesian-based probability of 
DLT on this arm was 7.2% (95% CI 2.8 -14.4%). The grade 5 
AEs occurred at a mean 13 mo postSBRT (range 5.5-14mo). 
 
 
 
Conclusion: The rates of toxicity pre-specified as DLT were 
relatively low. The highest dose level allowed by the protocol 
was reached, and associated with 7.2% rate of DLT. This 
phase I/II trial of SBRT provides data to inform patients of 
the potential toxicities with a 5 fraction SBRT schedule for 
centrally located NSCLC, but data on efficacy are still 
awaited. 
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Purpose or Objective: Patients with early stage non-small 
lung carcinoma (NSCLC) located centrally within the thorax 
present a therapeutic challenge with stereotactic body 
radiation therapy (SBRT). We compared outcomes of early 
stage NSCLC located in central and peripheral locations. 
 
Material and Methods: A total of 472 patients with early 
stage NSCLC were identified from a prospective IRB-approved 
thoracic SBRT registry. Tumors were classified as central if 
they were within 2 cm of the proximal bronchial tree or 
immediately adjacent to the mediastinal or pericardial 
pleura. Peripheral tumors were treated to 54 Gy in 3 
fractions, and central tumors to 50 or 55 Gy in 5 fractions. 
Patients were reviewed for overall survival (OS) calculated 
from completion of therapy and local failure (LF). The log-
rank test and Cox regression were used to identify factors 
predictive of OS and LF. 
 
Results: 127 patients had central tumors and 345 had 
peripheral tumors. Median follow-up was 30 months for living 
patients. For the entire cohort at 2 years, OS was 57% and LF 
was 10%. OS at 2 years was 50% for patients with central 
tumors and 60% for those with peripheral tumors (p=0.11). LF 
at 2 years was 19% for central lesions and 8% for peripheral 
lesions (p=0.08). On multivariate analysis, increasing tumor 
size (HR 1.21 per cm, 95% CI: 1.10-1.33, p<0.0001), 
increasing age-adjusted Charlson comorbidity score (HR 1.15 
per point, 95% CI: 1.09-1.20, p<0.0001), and worse KPS (HR 
10.1 per 10% loss, 95% CI: 10.1-10.2, p=0.0003), but not 
location predicted for worse OS. Only increasing tumor size 
(HR 1.37/cm, 95% CI: 1.06-1.78, p=0.02) predicted for LF on 
multivariate analysis. 
 
Conclusion: The use of five SBRT fractions of 10-11 Gy for 
central early stage NSCLC results in similar outcomes as 
peripheral early stage NSCLC treated in three SBRT fractions 
of 18 Gy. Larger tumors result in worse outcomes suggesting 
the need for additional treatment strategies. 
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Purpose or Objective: Pulmonary tumours are subject to 
respiratory motion which induces PET/MRI artefacts and 
imposes to use specific additional margins when treated by 
radiotherapy (RT). Gating techniques can solve these issues 
by stabilizing lung targets, and sustaining breath-holds in 
maximal inspiration (MI). However, these are limited by the 
patient’s capacity to hold his breath. The purpose of this 
work was to implement a new non-invasive respiratory 
assistance using high frequency percussive ventilation (HFPV -
Percussionaire®; Idaho, USA), and to report its first clinical 
use in maintaining breath holds long enough during chest 
imaging and complex RT treatments. 
 
Material and Methods: ethical committee approval was 
obtained to conduct a clinical study, after evaluating its 
